BMD changes up to 3 years following treatment with Zoladex or CMF in pre-/perimenopausal women with early breast cancer participating in the ZEBRA study.

I Fogelman; G M Blake

BMD changes up to 3 years following treatment with Zoladex or CMF in pre-/perimenopausal women with early breast cancer participating in the ZEBRA study.

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	S331 - S331
Journal	Journal of Bone and Mineral Research
Volume	16
Publication status	Published - 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{17ef294c3d354df8b46ceae87609f841,

title = "BMD changes up to 3 years following treatment with Zoladex or CMF in pre-/perimenopausal women with early breast cancer participating in the ZEBRA study.",

author = "I Fogelman and Blake, {G M}",

year = "2001",

language = "English",

volume = "16",

pages = "S331 -- S331",

journal = "Journal of Bone and Mineral Research",

issn = "1523-4681",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - BMD changes up to 3 years following treatment with Zoladex or CMF in pre-/perimenopausal women with early breast cancer participating in the ZEBRA study.

AU - Fogelman, I

AU - Blake, G M

PY - 2001

Y1 - 2001

M3 - Meeting abstract

SN - 1523-4681

VL - 16

SP - S331 - S331

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

ER -